PURPOSE: Targeting of cholecystokinin receptor expressing malignancies such as medullary thyroid carcinoma is currently limited by low in vivo stability of radioligands. To increase the stability, we have developed and preclinically evaluated two cyclic 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-minigastrin analogs radiolabeled with (111)In and (68)Ga. PROCEDURES: Radiolabeling efficiency, in vitro characterization, cholecystokinin receptor subtype 2 (CCK-2) binding in human tumor tissues, and cell internalization on CCK-2 receptor expressing AR42J cells, as well as biodistribution and small animal imaging in two different mouse xenograft models were studied. RESULTS: High receptor affinity and receptor-mediated uptake of the radioligands in AR42J cells was confirmed in vitro. (111)In-labeled cyclic DOTA-peptides showed a specific tumor uptake of ~1% ID/g in vivo, (68)Ga-labeled analogs of ~3% ID/g. Small animal SPECT imaging resulted to be superior with (111)In-DOTA-cyclo-MG2 in comparison with (111)In-DOTA-cyclo-MG1. CONCLUSIONS: Cyclic DOTA-minigastrin analogs are promising candidates for gastrin receptor scintigraphy and targeted radionuclide therapy.
PURPOSE: Targeting of cholecystokinin receptor expressing malignancies such as medullary thyroid carcinoma is currently limited by low in vivo stability of radioligands. To increase the stability, we have developed and preclinically evaluated two cyclic 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-minigastrin analogs radiolabeled with (111)In and (68)Ga. PROCEDURES: Radiolabeling efficiency, in vitro characterization, cholecystokinin receptor subtype 2 (CCK-2) binding in humantumor tissues, and cell internalization on CCK-2 receptor expressing AR42J cells, as well as biodistribution and small animal imaging in two different mouse xenograft models were studied. RESULTS: High receptor affinity and receptor-mediated uptake of the radioligands in AR42J cells was confirmed in vitro. (111)In-labeled cyclic DOTA-peptides showed a specific tumor uptake of ~1% ID/g in vivo, (68)Ga-labeled analogs of ~3% ID/g. Small animal SPECT imaging resulted to be superior with (111)In-DOTA-cyclo-MG2 in comparison with (111)In-DOTA-cyclo-MG1. CONCLUSIONS:Cyclic DOTA-minigastrin analogs are promising candidates for gastrin receptor scintigraphy and targeted radionuclide therapy.
Authors: M Cremonesi; M Ferrari; S Zoboli; M Chinol; M G Stabin; F Orsi; H R Maecke; E Jermann; C Robertson; M Fiorenza; G Tosi; G Paganelli Journal: Eur J Nucl Med Date: 1999-08
Authors: Elisabeth von Guggenberg; Werner Sallegger; Anna Helbok; Meltem Ocak; Robert King; Stephen J Mather; Clemens Decristoforo Journal: J Med Chem Date: 2009-08-13 Impact factor: 7.446
Authors: Martin Béhé; Wolfgang Becker; Martin Gotthardt; Christa Angerstein; Thomas M Behr Journal: Eur J Nucl Med Mol Imaging Date: 2003-05-24 Impact factor: 9.236
Authors: Frantisek Trejtnar; Milan Laznicek; Alice Laznickova; Martin Kopecky; Milos Petrik; Martin Béhé; Jörg Schmidt; Helmut Maecke; Theodosia Maina; Berthold Nock Journal: Anticancer Res Date: 2007 Mar-Apr Impact factor: 2.480
Authors: E von Guggenberg; H Dietrich; I Skvortsova; M Gabriel; I J Virgolini; C Decristoforo Journal: Eur J Nucl Med Mol Imaging Date: 2007-02-17 Impact factor: 10.057
Authors: Maximilian Klingler; Dominik Summer; Christine Rangger; Roland Haubner; Julie Foster; Jane Sosabowski; Clemens Decristoforo; Irene Virgolini; Elisabeth von Guggenberg Journal: J Nucl Med Date: 2018-12-07 Impact factor: 10.057
Authors: Marie Laval; Kathryn M Marshall; John Sachinidis; Andrew Scott; Mal Eutick; Graham S Baldwin Journal: J Biol Inorg Chem Date: 2017-07-12 Impact factor: 3.358
Authors: Theodosia Maina; Mark W Konijnenberg; Petra KolencPeitl; Piotr Garnuszek; Berthold A Nock; Aikaterini Kaloudi; Marko Kroselj; Katja Zaletel; Helmut Maecke; Rosalba Mansi; Paola Erba; Elisabeth von Guggenberg; Alicja Hubalewska-Dydejczyk; Renata Mikolajczak; Clemens Decristoforo Journal: Eur J Pharm Sci Date: 2016-05-14 Impact factor: 4.384